Völkl K P, Schneider B
Institut für Biometrie der Med. Hochschule Hannover.
Fortschr Med. 1992 Jun 30;110(18):346-50.
Open therapeutic observational study.
2,510 patients with acute and chronic bronchitis, bronchial asthma, and emphysema.
4-week treatment with N-acetylcystein administered three times a day 200 mg dissolved (n = 1734) or undissolved (n = 608) or at some other, usually lower, dosage (n = 173). During the f-week treatment phase, any other drugs being taken were neither discontinued nor changed. TARGET PARAMETERS: In addition to 1-sec capacity (FEV1), various, mainly subjective, parameters were noted, in particular coughing, amount and nature of expectorate.
for the evaluation, the patients were assigned either to the acute bronchitis or the chronic bronchitis group; the latter group also contained patients with other diseases, such as asthma and emphysema, since such conditions often presented simultaneously. All selected parameters clearly improved under treatment, equally in the acute and chronic bronchitis groups. As expected, the mucolytic effect was very pronounced, the 1-sec capacity increased significantly. No major difference was to be found in the results observed in patients on and those not on other additional medication.
开放性治疗观察性研究。
2510例患有急慢性支气管炎、支气管哮喘和肺气肿的患者。
用N-乙酰半胱氨酸进行为期4周的治疗，每日给药3次，200毫克溶解服用（n = 1734）或未溶解服用（n = 608），或采用其他通常较低的剂量（n = 173）。在为期5周的治疗阶段，正在服用的任何其他药物既不停用也不改变。目标参数：除了1秒用力呼气容积（FEV1）外，还记录了各种主要为主观性的参数，特别是咳嗽、咳痰量和性质。
为了进行评估，患者被分为急性支气管炎组或慢性支气管炎组；后者组还包括患有其他疾病（如哮喘和肺气肿）的患者，因为这些病症常同时出现。所有选定的参数在治疗后均明显改善，急性和慢性支气管炎组情况相同。正如预期的那样，黏液溶解作用非常显著，1秒用力呼气容积显著增加。在服用和未服用其他附加药物的患者中观察到的结果没有重大差异。
